RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men
about
Attenuation of pathogenic immune responses during infection with human and simian immunodeficiency virus (HIV/SIV) by the tetracycline derivative minocyclineBeneficial effect of TRAIL on HIV burden, without detectable immune consequences.Short-term bone loss in HIV-infected premenopausal womenElevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic ratsElevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross-sectional studyAging, human immunodeficiency virus, and bone health.Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infectionHIV-1 protein induced modulation of primary human osteoblast differentiation and function via a Wnt/β-catenin-dependent mechanism.Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients.Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies.Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patientsPerturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.Bone health in children and adolescents with perinatal HIV infectionColony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing.Adverse bone health among children and adolescents growing up with HIV.Low bone mineral density and associated risk factors in HIV-infected patients.Does systemic inflammation and immune activation contribute to fracture risk in HIV?Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patientsHIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV InfectionRole of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.Continuous antiretroviral therapy decreases bone mineral density.Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION.Bone health in persons with haemophilia: a review.Bone health and human immunodeficiency virus infection.HIV infection, bone metabolism, and fractures.Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.HIV-1 replicates in human osteoclasts and enhances their differentiation in vitro.Bone mineral density in people living with HIV: a narrative review of the literature.Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.Bone metabolism dysfunction mediated by the increase of proinflammatory cytokines in chronic HIV infection.The clinical utility of bone turnover markers in the evaluation of bone disease in patients with haemophilia A and B.Hypovitaminosis D and osteopenia/osteoporosis in a haemophilia population: a study in HCV/HIV or HCV infected patients.Bone degradation machinery of osteoclasts: An HIV-1 target that contributes to bone loss.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.The Hidden Burden of Fractures in People Living With HIV
P2860
Q27342233-D306BA81-40FA-4525-A1C4-3D83287A8405Q33366417-2375F6CC-86A5-40AA-B92C-BA5667A881E4Q33618567-2957F570-0BDD-4B47-A20D-EF876FF7F397Q33723186-310C169E-AFB2-47D6-AF72-5BE7D705667CQ33811250-419ED5BC-F644-4650-9C6C-FF916BDD1E29Q34160511-0E836266-DD8A-4695-8101-36CC59B44FDCQ34506677-AA418C66-EB4C-4FFF-B04A-0E70AABED337Q34529322-CBC67F19-36AF-4FFF-84BF-986C8CDED919Q35124970-7392103B-B305-434F-ADDE-50D39547585BQ35578707-CC169B55-853B-479E-91EA-55DD2DBB2293Q36071793-98A4E3E1-F3EF-422A-9D3B-1B665FDC6CD2Q36154208-1C4E9D6F-B2EE-4691-A90D-521EA23C43D8Q36688486-234F427E-F25D-488A-A3D9-89850786E73CQ36842216-7EE16FA9-DD53-476F-86A5-7E6B3A1E57B8Q36941678-912FC755-3522-4B25-ABE9-90893B21BC2FQ37073330-13668539-A71D-41F4-926C-D8289FE73467Q37098360-2EDED6C7-9397-455E-8889-C2CEE97162DFQ37115224-0030DBE4-338B-4B36-81BB-A0BBA166BC96Q37138907-DDBB7F02-380C-4B88-BA1B-BB7D9A3BF28EQ37155840-98CDC46B-1F9A-4A8A-9265-86A8C32DEC23Q37304461-0464860F-3546-4263-8B94-FF8FAD8DCD92Q37344527-00A99D63-9AE8-4514-A326-0966D4A02C05Q37357149-5CA94BB8-C69C-4272-AD36-B88E405E6041Q37589696-AB12724E-D369-44CF-95D4-01FDB208632FQ37725096-5D019F01-A910-4000-83C8-AB0241CA9420Q38010249-EE7129A0-74EE-4E43-B778-45FCC7BF85EDQ38095828-52E2A3A0-DF62-4844-B852-1FBCD66217FCQ38244166-A38DB19A-66E7-4F3D-8480-F5C2543B2252Q39015984-1844DB64-6847-40B8-8CF3-D5F0F33BF3E9Q39026321-7460E04B-1B6E-4AE6-9BAB-911F75CC3901Q40107245-8586BCFE-B043-40B7-B811-B672A0F5E132Q40158081-D9C4EE34-96B1-4DBC-9843-EB20A18016DFQ40736447-98B1C723-8ED2-4613-9B79-10B74A610C11Q42263129-9923A309-A53C-4166-B91C-E7E95B0008B5Q45880333-7166C018-690D-44FA-810A-97087C89804AQ49790704-514B7F57-1EB5-42CA-BA80-1BD7D6282E61Q51760860-2A202028-5EA0-49EF-BD56-84B922811123Q57143538-8872AAFA-ACD1-4B96-8316-EC487B336024
P2860
RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2007
@uk
name
RANKL/OPG/TRAIL plasma levels ...... viral naive HIV-1-positive men
@en
RANKL/OPG/TRAIL plasma levels ...... viral naive HIV-1-positive men
@nl
type
label
RANKL/OPG/TRAIL plasma levels ...... viral naive HIV-1-positive men
@en
RANKL/OPG/TRAIL plasma levels ...... viral naive HIV-1-positive men
@nl
prefLabel
RANKL/OPG/TRAIL plasma levels ...... viral naive HIV-1-positive men
@en
RANKL/OPG/TRAIL plasma levels ...... viral naive HIV-1-positive men
@nl
P2093
P356
P1476
RANKL/OPG/TRAIL plasma levels ...... viral naive HIV-1-positive men
@en
P2093
Davide Gibellini
Elisa De Crignis
Fabio Vescini
Francesco Chiodo
Marco Borderi
Renata Caudarella
Ronny Cicola
P304
P356
10.1002/JMV.20938
P407
P577
2007-10-01T00:00:00Z